23.02.2018 kl 08:07 4634


The United States Patent and Trademark Office (USPTO) has communicated
its intention to grant a new US patent in the portfolio licensed to
Redwood Pharma from Broda International LLC. A new US patent will,
when granted, provide enhanced patent protection in the United States
for the so-called IntelliGel platform, which is used, inter alia, in
the development of Redwood Pharmas RP101 product.

We are very pleased that the protection of RP101, our drug for the
treatment of chronic dry eye in women, and for other ophthalmological
products, will be strengthened. As soon as the patent is granted, it
will expand the protection of possible hydrogel compositions and
innovative ways of obtaining them. Redwood Pharma secures the
protection through an integrated IP strategy implemented by the
company and by the licensor Broda International. We thank our
licensing partners for their continued innovations and for continuing
to seek IP protection, says CEO Martin Vidaeus.

About IntelliGel
IntelliGel is Redwood Pharmas exclusive technology for delivering
drug to the front of the eye with a new hydrogel based on poloxamers
and water. IntelliGel is applied as eye drop and gels on contact with
the eye. This transparent, lubricating, reversible thermogel can
increase the bioavailability of the active substance, as the gel
holds the drug in the eye for longer. This, in turn, allows for a
reduction of the amount of active substance administered, a reduction
in the number of doses and possible side effects related to the
active substance. IntelliGel is currently used in dermatological
products sold commercially in the US and China. IntelliGel can be
used for prescription products as well as for OTC products.

For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29

This information is information that Redwood Pharma AB is obliged to
make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the
contact persons set out above, at February 23, 2017.

About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs.
The Companys first project is the development of drug candidate
RP101 with a known active substance against chronic dry eye in
postmenopausal women who have moderate to severe symptoms. With the
drug delivery platform IntelliGel the release of active substances
is controlled. Through the use of IntelliGel, Redwood Pharma can also
improve dosing of other established drugs. Redwood Pharmas strength
lies in formulation and early clinical development. Revenues will be
generated through licensing agreements with pharmaceutical companies
that have capabilities to manufacture and sell commercial products

Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish
Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).

For more information visit:


Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.